Company to Host Conference Call Today, Thursday, October 13, 2016 at 8:00 a.m.
EDT
BOTHELL, Wash. and VANCOUVER, British Columbia, Oct. 13, 2016 /CNW/ -- OncoGenex
Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today results from
the final analysis of the Phase 3 ENSPIRIT trial of custirsen in
patients whose non-small cell lung cancer (NSCLC) has progressed
following initial treatments. The trial did not meet the primary
endpoint of demonstrating a statistically significant improvement
in overall survival for patients treated with custirsen in
combination with docetaxel compared to docetaxel alone. The
median overall survival for the custirsen arm was 9.0 months versus
7.9 months for the control arm with a hazard ratio of 0.915
(one-sided p=0.178). Safety results were consistent with
those observed in previous trials of custirsen in combination with
chemotherapy.
"Following the negative results of previous custirsen trials, an
early final analysis of the ENSPIRIT trial was conducted in an
effort to conserve capital and extend our cash runway," said
Scott Cormack, President and CEO of
OncoGenex. "We will continue to take appropriate steps to realize
the most value for our shareholders once we receive the results of
our apatorsen Phase 2 Borealis-2 bladder cancer trial which are
expected by the end of October."
OncoGenex is continuing to work with MTS Health Partners who has
been advising the company in the exploration of strategic
alternatives since mid-August.
"OncoGenex is grateful to the patients who participated in the
ENSPIRIT trial and their families for their support, as well as our
investigators and our employees for their commitment to improving
cancer care for those who need it most," Cormack continued.
Conference Call Details
OncoGenex will host a
conference call at 8:00 a.m. Eastern
Time today, Thursday, October 13,
2016, to discuss today's news. A live event will be
available on the Investor Relations section of the OncoGenex
website at www.OncoGenex.com. Alternatively, visitors may access
the live conference call by dialing (877) 606-1416 (U.S. &
Canada) or (707) 287-9313
(International). A webcast replay will be available approximately
two hours after the call and will be archived
on www.OncoGenex.com for 90 days.
About the Phase 3 ENSPIRIT Trial
The Phase 3 ENSPIRIT trial is an international, randomized,
open-label trial designed to evaluate custirsen for the treatment
of advanced or metastatic NSCLC in patients who have progressed
after initial chemotherapy treatment. The trial investigated
if combining custirsen with docetaxel, a standard second-line NSCLC
chemotherapy, has the potential to improve survival outcomes
compared to docetaxel alone in these patients. The trial enrolled
664 patients at approximately 50 sites globally.
For more information on the ENSPIRIT trial, please
visit http://clinicaltrials.gov/ct2/show/NCT01630733.
About the Borealis-2 Trial
Borealis-2 is an
investigator-sponsored, randomized Phase 2 trial evaluating a
survival benefit with apatorsen in combination with docetaxel
treatment compared to docetaxel treatment alone in approximately
200 patients with metastatic bladder cancer who have disease
progression following first-line platinum-based chemotherapy.
The trial is being coordinated by the Hoosier Cancer Research
Network at 27 sites across the United States.
About OncoGenex
OncoGenex is a biopharmaceutical
company committed to the development and commercialization of new
therapies that address treatment resistance in cancer patients.
OncoGenex has a diverse oncology pipeline, with each product
candidate having a distinct mechanism of action and representing a
unique opportunity for cancer drug development. Apatorsen is in
Phase 2 clinical development and OGX-225 is currently in
pre-clinical development. More information is available at
www.OncoGenex.com and at the company's Twitter account:
https://twitter.com/OncoGenex_IR.
OncoGenex' Forward Looking Statements
This press
release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995, including, but not limited to, statements
regarding the potential benefits and development of our product
candidates and business strategies. All statements other than
statements of historical fact are statements that could be deemed
forward-looking statements. These statements are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and assumptions that could cause
actual results to differ materially from those described in the
forward-looking statements. Such risks and uncertainties include,
among others, the risk that our product candidates do not
demonstrate the hypothesized or expected benefits, the risk that we
cannot achieve our business strategies including the completion of
strategic transactions, the risk that new developments in the
rapidly evolving cancer therapy landscape require changes in our
clinical trial plans or limit the potential benefits of our
products and the other factors described in our risk factors set
forth in our filings with the Securities and Exchange Commission
from time to time, including the Company's Annual Report on Form
10-K and Quarterly Reports on Form 10-Q. The Company undertakes no
obligation to update the forward-looking statements contained
herein or to reflect events or circumstances occurring after the
date hereof, other than as may be required by applicable law.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncogenex-announces-results-from-the-phase-3-enspirit-trial-of-custirsen-in-non-small-cell-lung-cancer-300343975.html
SOURCE OncoGenex Pharmaceuticals, Inc.